secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016259
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q2 net loss $14.9M, cash $131.9M; Phase 2b atacicept enrollment complete
--------------------------------------------------------------------------------

- Net loss of $14.9M ($0.55 per share) vs $3.4M ($0.33) in Q2 2021.
- Cash, equivalents, and securities $131.9M at June 30, 2022; plus $45M credit facility.
- Completed enrollment in Phase 2b ORIGIN trial of atacicept for IgA nephropathy; topline data expected early Q1 2023.
- Appointed Michael M. Morrissey, Ph.D., CEO of Exelixis, as Chairman of the board.
- Plan to initiate Phase 3 atacicept trial in lupus nephritis in H2 2022 and Phase 2b/3 MAU868 in BKV in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017022016259/0000950170-22-016259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017022016259/vera-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer